217 related articles for article (PubMed ID: 25849323)
1. 1H NMR-based metabolomics investigation of copper-laden rat: a model of Wilson's disease.
Xu J; Jiang H; Li J; Cheng KK; Dong J; Chen Z
PLoS One; 2015; 10(4):e0119654. PubMed ID: 25849323
[TBL] [Abstract][Full Text] [Related]
2.
Pu Y; Zhang J; Peng N; Li R; Xie DJ; Zhang RX; Sun LT; Wang JL; Ye H
J Pharm Biomed Anal; 2023 May; 229():115355. PubMed ID: 37018958
[TBL] [Abstract][Full Text] [Related]
3. Metabolic profiling of copper-laden hepatolenticular degeneration model rats and the interventional effects of Gandou decoction using UPLC-Q-TOF/MS.
Cheng M; Wu H; Wu H; Liu X; Zhou A
J Pharm Biomed Anal; 2019 Feb; 164():187-195. PubMed ID: 30390561
[TBL] [Abstract][Full Text] [Related]
4. Liver and urine metabolomics reveal the protective effect of Gandou decoction in copper-laden Hepatolenticular degeneration model rats.
Xu R; Liang J; Cheng M; Wu H; Wu H; Cao S; Zhao W; Xu R; Zhou A
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1179():122844. PubMed ID: 34246170
[TBL] [Abstract][Full Text] [Related]
5. Spatial investigation of the elemental distribution in Wilson's disease liver after d-penicillamine treatment by LA-ICP-MS.
Hachmöller O; Zibert A; Zischka H; Sperling M; Groba SR; Grünewald I; Wardelmann E; Schmidt HH; Karst U
J Trace Elem Med Biol; 2017 Dec; 44():26-31. PubMed ID: 28965585
[TBL] [Abstract][Full Text] [Related]
6. DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease.
Krishnan N; Felice C; Rivera K; Pappin DJ; Tonks NK
Genes Dev; 2018 Jul; 32(13-14):944-952. PubMed ID: 29945887
[TBL] [Abstract][Full Text] [Related]
7. Wilson's disease: clinical, genetic and pharmacological findings.
Leggio L; Addolorato G; Abenavoli L; Gasbarrini G
Int J Immunopathol Pharmacol; 2005; 18(1):7-14. PubMed ID: 15698506
[TBL] [Abstract][Full Text] [Related]
8. ARBM101 (Methanobactin SB2) Drains Excess Liver Copper via Biliary Excretion in Wilson's Disease Rats.
Einer C; Munk DE; Park E; Akdogan B; Nagel J; Lichtmannegger J; Eberhagen C; Rieder T; Vendelbo MH; Michalke B; Wimmer R; Blutke A; Feuchtinger A; Dershwitz P; DiSpirito AM; Islam T; Castro RE; Min BK; Kim T; Choi S; Kim D; Jung C; Lee H; Park D; Im W; Eun SY; Cho YH; Semrau JD; Rodrigues CMP; Hohenester S; Damgaard Sandahl T; DiSpirito AA; Zischka H
Gastroenterology; 2023 Jul; 165(1):187-200.e7. PubMed ID: 36966941
[TBL] [Abstract][Full Text] [Related]
9. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.
Gupta P; Choksi M; Goel A; Zachariah U; Sajith KG; Ramachandran J; Chandy G; Kurian G; Rebekah G; Eapen CE
Indian J Gastroenterol; 2018 Jan; 37(1):31-38. PubMed ID: 29457214
[TBL] [Abstract][Full Text] [Related]
10. The effect of certain chelating compounds on the urinary excretion of copper by the rat: observations on their clinical significance.
Gibbs K; Walshe JM
Clin Sci Mol Med; 1977 Oct; 53(4):317-20. PubMed ID: 913055
[TBL] [Abstract][Full Text] [Related]
11. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.
Lozano Herrero J; Muñoz Bertrán E; Ortega González I; Gómez Espín R; López Espín MI
Gastroenterol Hepatol; 2012 Dec; 35(10):704-7. PubMed ID: 22609346
[TBL] [Abstract][Full Text] [Related]
12. Pathological mitochondrial copper overload in livers of Wilson's disease patients and related animal models.
Zischka H; Lichtmannegger J
Ann N Y Acad Sci; 2014 May; 1315():6-15. PubMed ID: 24517326
[TBL] [Abstract][Full Text] [Related]
13. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
Hoogenraad TU
Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
[TBL] [Abstract][Full Text] [Related]
14. The link between copper and Wilson's disease.
Purchase R
Sci Prog; 2013; 96(Pt 3):213-23. PubMed ID: 24244969
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of oxidative events and copper accumulatıon in oral tissues of patients wıth Wilson's disease: three case report.
Ozturk M; Karacelebi E; Gungor K; Coskun S; Boysan E
Int J Clin Exp Pathol; 2015; 8(4):3943-5. PubMed ID: 26097579
[TBL] [Abstract][Full Text] [Related]
16. Current Drug Managements of Wilson's Disease: From West to East.
Li WJ; Chen C; You ZF; Yang RM; Wang XP
Curr Neuropharmacol; 2016; 14(4):322-5. PubMed ID: 26639459
[TBL] [Abstract][Full Text] [Related]
17. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
Purchase R
Sci Prog; 2013; 96(Pt 1):19-32. PubMed ID: 23738435
[TBL] [Abstract][Full Text] [Related]
18. Protection from spontaneous hepatocellular damage by N-benzyl-d-glucamine dithiocarbamate in Long-Evans Cinnamon rats, an animal model of Wilson's disease.
Shimada H; Takahashi M; Shimada A; Okawara T; Yasutake A; Imamura Y; Kiyozumi M
Toxicol Appl Pharmacol; 2005 Jan; 202(1):59-67. PubMed ID: 15589977
[TBL] [Abstract][Full Text] [Related]
19. [The onset of psychiatric disorders and Wilson's disease].
Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
[TBL] [Abstract][Full Text] [Related]
20. Effects of copper toxicity on response inhibition processes: a study in Wilson's disease.
Stock AK; Reuner U; Gohil K; Beste C
Arch Toxicol; 2016 Jul; 90(7):1623-30. PubMed ID: 26438404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
